リベロセラ株式会社 focuses on drug discovery against GPCR and other membrane protein targets, pursuing antibody medicines and antibody–drug conjugates. The company leverages a cell-free membrane protein expression technology developed by 横山茂之博士 to overcome difficulties in membrane protein expression and purification. Founded in April 2018 and based in Nihonbashi, Chuo‑ku, Tokyo, リベロセラ also provides related discovery services around membrane-protein targets. Management says its current therapeutic candidates are intended to be first-in-class and address diseases with high unmet need. The company plans to use recent funding to validate candidates in cell and animal models and to strengthen capabilities to carry nonclinical work through to early clinical development.

Total raised

$1M

Funding rounds

1

Latest round

Equity

Latest activity

Aug 2024